Do I qualify for Inspire? Current criteria explained

"Do I qualify for Inspire?" is two questions. The FDA label is one set of numbers. Medicare is another, stricter set. Commercial plans often sit closer to the label, but that is not a promise about your Ohio card. DISE still sits in the middle for anyone who needs the implant paid as hypoglossal nerve stimulation.

Why do the numbers disagree?

Inspire is an implanted hypoglossal-nerve stimulator. A chest generator, a breathing sensor, and a cuff on the nerve that moves the tongue forward during sleep. The current implantable pulse generator is Inspire V, Model 3150, approved 1 August 2024 as PMA supplement P130008/S098.

The indication expansion that patients actually quote is older. On 8 June 2023, PMA supplement S090 raised the labeled AHI upper limit from 65 to 100 events per hour and raised the BMI warning from 32 to 40. FDA’s recently-approved-devices summary describes the adult indication as moderate to severe obstructive sleep apnea, 15 ≤ AHI ≤ 100, age 22 and older, in people who have failed or not tolerated PAP. There are additional labeled bands for ages 18 to 21 and for adolescents with Down syndrome. This article is about typical adult care in a Westerville clinic, not pediatric pathways.

Medicare LCD L38310 (revision effective 16 October 2025 on the copy opened for this article) does not follow that expansion all the way. Covered indications, all of them required:

	FDA labeling (S090, 2023)	Medicare LCD L38310
Age	22+ for the adult indication quoted here	22 or older
AHI	15-100	15-65
BMI	Warning upper limit 40	Less than 35 kg/m²
Sleep study	Diagnostic testing required	PSG within 24 months of first HGNS consultation
Event type	Obstructive disease; central/mixed limits exist in selection literature	Central and mixed < 25% of total AHI
PAP	Failed or not tolerated	Failure (AHI > 15 despite use) or intolerance (< 4 hours/night, 5 nights/week, or device returned), plus shared decision-making after a sleep expert
DISE	Used in STAR selection; complete concentric collapse excluded patients from the pivotal trial	Required: no complete concentric collapse at the soft palate
Anatomy	Must be a candidate for the implant	No anatomy that would compromise the device (example: tonsil size 3 or 4)

If you are 58, AHI 72, BMI 37, and Medicare is the payer, the FDA label is not the coverage rule. If you are commercially insured, the plan may use the FDA window. the live PDF for your Ohio carrier before anyone treats “BMI 40” as a paid indication.

Ohio fee-for-service claims go to CGS Administrators. CGS LCD L38307 uses the same eight covered indications as L38310: age 22 or older, BMI less than 35, PSG within 24 months of the first implant consult, predominantly obstructive events, AHI 15 to 65, CPAP failure or intolerance with shared decision making, no complete concentric collapse on DISE, and no anatomy that would compromise the device (tonsil size 3 or 4 is the example). Medicare Advantage still runs its own prior authorization on top of those clinical lines.

Do you have to fail CPAP?

For Medicare, yes, in a documented way. Failure means residual AHI greater than 15 despite using the machine. Intolerance means less than 4 hours per night, 5 nights per week, or the device has been returned. That is not the same sentence as the PAP coverage rule on LCD L33718, which looks for at least 4 hours on 70% of nights in a 30-day window during the first 90 days. Mixing those two numbers in a prior-auth letter is how packets bounce.

Clinically, intolerance is broader: claustrophobia, leak that never settles, aerophagia, insomnia on the mask. Payers still want a download or a return. If you never really had a supported CPAP trial, the implant conversation usually starts there, not in an operating room.

People looking at CPAP alternatives should also know oral appliances and, for obesity with moderate to severe OSA, tirzepatide exist. An implant is not the only door after a bad mask month.

Why is DISE not optional?

Drug-induced sleep endoscopy watches the palate under sedation. Complete concentric collapse at the soft palate was an exclusion in STAR and is a coverage exclusion on L38310. If the airway closes in a concentric ring, stimulating the tongue does not fix the collapse the trial was built around.

DISE is its own procedure, with its own risks and its own bill. It is not a “quick look in clinic.” There is a separate article on this site about what DISE feels like. The qualification point is simpler: no DISE, no honest Medicare packet.

What did the trial actually show?

STAR (Strollo et al., NEJM 2014) implanted 126 adults, 83% men, mean age 54.5, mean BMI 28.4. Median AHI went from 29.3 to 9.0 events per hour at 12 months. Median oxygen desaturation index 25.4 to 7.4. Sixty-six percent met the AHI responder definition (at least 50% reduction and AHI under 20). It was an uncontrolled cohort with a randomized withdrawal substudy, not a fully randomized pivotal against sham implant for the 12-month primary analysis. That matters for how strongly anyone should sell “this always works.”

The 2023 AHI and BMI expansion leaned on the ADHERE registry. This article does not reprint ADHERE subgroup deltas that were not extracted from the SSED in the research pass. those cells before quoting them in marketing copy.

What should you do with this list?

Bring a recent sleep study, a CPAP download if you have one, and a medication list to an insurance conversation that happens before anyone schedules implant. BMI and AHI are measured, not guessed from clothes size. If the study is older than 24 months and the payer is Medicare, it will need repeating.

Qualification is not a vibe and it is not a website quiz. Call (614) 898-9340 if you want Dr. Qadoom to read the numbers against the label and against the payer that will actually be billed. Hours are Monday through Friday, 8:00 AM to 5:00 PM, at 450 Alkyre Run Drive, Suite 230, Westerville, OH 43082.

Who is clearly not a candidate on Medicare’s list?

L38310 also lists limitations that are easy to miss if you only memorize AHI and BMI. Central and mixed events over 25% of AHI. BMI 35 or higher. Neuromuscular disease. Hypoglossal-nerve palsy. Severe restrictive or obstructive lung disease. Moderate-to-severe pulmonary arterial hypertension. Severe valvular heart disease. NYHA class III or IV heart failure. Recent myocardial infarction or severe arrhythmias within six months. Persistent uncontrolled hypertension on medication. Active serious mental illness that would keep someone from operating the remote and reporting problems. Coexisting nonrespiratory sleep disorders that would confound functional assessment. Pregnancy or plans to become pregnant. An existing implant that could interact with the system.

STAR itself excluded complete concentric collapse, large tonsils, and several of those medical comorbidities. The LCD is stricter than a social-media “AHI 20, let’s implant” pitch. A person can be a technical FDA candidate and still be a Medicare no.

If the study that produced your AHI was a home test, Medicare wants a PSG within 24 months of the first HGNS consultation. Home tests have a role in diagnosing uncomplicated OSA. They are not automatically the study an implant packet will accept. That is another reason the Inspire therapy pathway starts in clinic, not in a device brochure.

Shared decision-making is named in the intolerance clause. It means a documented conversation with a sleep expert, not a signature on a device-company iPad in a hallway. Bring questions about battery replacement, MRI conditions for the specific generator, residual AHI, and what happens if DISE shows concentric collapse. Those answers change the plan more than a BMI of 34.9 versus 35.1 on a bad scale day.